Rilmazolam

From Wikipedia, the free encyclopedia
Rilmazolam
Rilmazafone metabolite.svg
Clinical data
Trade names(none, active metabolite of Rilmazafone)
Legal status
Legal status
  • Generally Legal
Identifiers
  • 8-chloro-6-(2-chlorophenyl)-N,N-dimethyl-4H-[1,2,4]triazolo[1,5-a][1,4]benzodiazepine-2-carboxamide
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
3D model (JSmol)
  • CN(C)C(=O)C1=NN2C(=N1)CN=C(C3=C2C=CC(=C3)Cl)C4=CC=CC=C4Cl
  • InChI=InChI=1S/C19H15Cl2N5O/c1-25(2)19(27)18-23-16-10-22-17(12-5-3-4-6-14(12)21)13-9-11(20)7-8-15(13)26(16)24-18/h3-9H,10H2,1-2H3
  • Key:YMJXPUGNWIWFJI-UHFFFAOYSA-N

Rilmazolam, is a benzodiazepine derivative which acts as a sedative and hypnotic drug, and the active metabolite of the drug Rilmazafone.[1] It has never been developed for medical uses, yet the aforementioned prodrug is an approved medication in Japan.

See also[edit]

References[edit]

  1. ^ Koike M, Norikura R, Sugeno K (March 1986). "Intestinal activation of a new sleep inducer 450191-S, a 1H-1,2,4-triazolyl benzophenone derivative, in rats". Journal of Pharmacobio-Dynamics. 9 (3): 315–20. doi:10.1248/bpb1978.9.315. PMID 3454653.